Cantargia AB (publ) (STO:CANTA)

Market Cap	1.04B
Revenue (ttm)	308.69M
Net Income (ttm)	139.93M
Shares Out	248.61M
EPS (ttm)	0.60
PE Ratio	6.95
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,086,759
Average Volume	5,045,143
Open	4.250
Previous Close	4.240
Day's Range	4.130 - 4.330
52-Week Range	1.000 - 4.775
Beta	1.75
RSI	55.78
Earnings Date	Feb 20, 2026

About Cantargia AB

Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in phase 1 clinical trial for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 22
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: CANTA